Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chilean male within 18 and 50 years old.~* To have accepted his voluntary participation through the sign of the informed consent.~* To be in good health, according to the medical history, physical examination and normal laboratory tests.~* To be vaccinated with BCG once or twice during his life.~Exclusion Criteria:~* Symptoms or diagnosis suggesting some systemic disease including renal, liver, cardiovascular or pulmonary impairment, immunodeficiency, autoimmune disease, malignancies, psychiatric or other conditions that can interfere on the interpretation of the results or compromise the health of the participants.~* Body mass index lower than 19 and higher that 30 kg/m2 and/or weight under 50 kg.~* Not being able to attend all the study visits (face-to-face and call phones) or not follow the specified instructions (fasting, not doing intense physical exercise during the previous 24 hours to the visits and 72 hours post-vaccine).~* Signs of latent or active infectious diseases by Mycobacterium tuberculosis (TB): QuantiFERON-TB positive test or Chest X-ray suggesting Tuberculosis (TBC).~* Positive screening for Human Immunodeficiency Virus (HIV), Hepatitis B superficial antigen (HBsAG) and anti-Hepatitis C Virus (HCV).~* Evidence of primary or secondary immunodeficiency, determined by history, physical test and levels of serum immunoglobulins and lymphocytes sub-populations at the screening.~* Use of immunosuppressors during the last 6 months previous to the visit.~* Use of inhaled corticosteroids during the last year or with antecedents of bronchial hyper-reactivity.~* Antecedents of intradomiciliary contact with subjects with Tuberculosis or other mycobacteria, even when he/she is under treatment.~* Antecedents of substance abuse (drugs or alcohol), according to DSM IV (See footnote\*)~* Occurrence of any serious adverse event associated to the previous BCG vaccination.~* History of severe allergic reaction or anaphylaxis to vaccines~* History of severe infections (use of IV antibiotics, opportunist, latent TBC, herpes zoster) during six months previous to the visit.~* Not use or rejection to the use of contraceptives during the whole study (See footnote\*\*).~* Administration of Immunoglobulins or blood-derived products during the six months previous to the visit or the planning of its use during the study.~* Eczema at the vaccination site (deltoid zone).~* Antecedents of keloid scar.~* Being vaccinated with BCG during the last 10 years.~* History of being vaccinated with BCG three or more times or the presence of three BCG scars.~* Using other investigational products during the 30 days previous to the study.~* Administration of any vaccine during the 8 weeks previous to the recruitment.~* Planned administration of any other different vaccine 30 days after the vaccination with the rBCG-N-hRSV.~* Acute illness symptoms and/or feverish symptoms at the time or during the last seven days previous to the recruitment (fever defined as an oral or axillary temperature of \>38ºC).~(\*) Substance abuse (drugs or alcohol): Maladaptive pattern of substance abuse that leads to a deterioration or clinical significant discomfort, expressed by one or more associated problems, during a time of twelve months, in one of the four vitals areas: inability to achieve main obligations; consume in dangerous situations, such as driving a vehicle; legal problems; consume despite the social and interpersonal difficulties associated.~(\*\*) Given the remote possibility of negative effects produced by the vaccination in the sperm, the recruitment will be performed only to volunteers that are not planning of conceiving a child during the study duration. In each visit, the abstinence fulfillment will be checked or the use of effective contraceptive.~Eligibility criteria:~The eligibility of the volunteers will be performed if they fulfill the inclusion criteria and fulfill none of the mentioned exclusion criteria, also presenting all the normal screening study.~All the volunteers must sign the Informed consent approved by the Ethic Committee of the Facultad de Medicina of the Pontificia Universidad Católica de Chile, before starting the first screening visit.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Conventional BCG full dose (Type: ACTIVE_COMPARATOR): Participants will receive one full dose of the Conventional BCG vaccine administered as an intradermal injection at study entry.
- rBCG-N-hRSV 1/100 dose (Type: EXPERIMENTAL): Participants will receive one 1/100 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
- rBCG-N-hRSV 1/10 dose (Type: EXPERIMENTAL): Participants will receive one 1/10 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
- rBCG-N-hRSV full dose (Type: EXPERIMENTAL): Participants will receive one full dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete